Expressed Protein Ligation in Flow.


Journal

Journal of the American Chemical Society
ISSN: 1520-5126
Titre abrégé: J Am Chem Soc
Pays: United States
ID NLM: 7503056

Informations de publication

Date de publication:
25 Jul 2024
Historique:
medline: 26 7 2024
pubmed: 26 7 2024
entrez: 25 7 2024
Statut: aheadofprint

Résumé

The development of a flow chemistry platform for the generation of modified protein targets via expressed protein ligation (EPL) is described. The flow EPL platform enables efficient ligation reactions with high recoveries of target protein products and superior reaction rates compared to corresponding batch processes. The utility of the flow EPL technology was first demonstrated through the semisynthesis of the tick-derived chemokine-binding protein ACA-01 containing two tyrosine sulfate modifications. Full-length, sulfated ACA-01 could be efficiently assembled by ligating a recombinantly expressed C-terminal protein fragment and a synthetic sulfopeptide thioester in flow. Following folding, the semisynthetic sulfoprotein was shown to exhibit potent binding to a variety of pro-inflammatory chemokines. In a second modified protein target, we employed an in-line flow EPL-photodesulfurization strategy to generate both unmodified and phosphorylated forms of human β-synuclein by fusing a recombinant protein thioester, generated through cleavage of an intein fusion protein, and a synthetic (phospho)peptide. The semisynthetic proteins were assembled in 90 min in flow, a significant improvement over corresponding batch protein assembly, and enabled access to tens of milligrams of high purity material. Flow EPL has the potential to serve as a robust technology to streamline access to homogeneously modified proteins for a variety of applications in both academia, as well as in the pharmaceutical and biotechnology sector.

Identifiants

pubmed: 39052634
doi: 10.1021/jacs.4c07462
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Lucas Kambanis (L)

School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, NSW 2006, Australia.

Anthony Ayoub (A)

School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, NSW 2006, Australia.

Max J Bedding (MJ)

School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, NSW 2006, Australia.

Peter H G Egelund (PHG)

School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, NSW 2006, Australia.
Novo Nordisk A/S, CMC API Development, DK-2880 Bagsværd, Denmark.

Joshua W C Maxwell (JWC)

School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, NSW 2006, Australia.

Charlotte Franck (C)

School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, NSW 2006, Australia.

Lucien Lambrechts (L)

School of Life and Environmental Sciences, The University of Sydney, Sydney, NSW 2006, Australia.

Paige M E Hawkins (PME)

School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, NSW 2006, Australia.

Timothy S Chisholm (TS)

School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, NSW 2006, Australia.

Joel P Mackay (JP)

School of Life and Environmental Sciences, The University of Sydney, Sydney, NSW 2006, Australia.

Emma Sierecki (E)

Department of Molecular Medicine, School of Biomedical Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, University of New South Wales, Sydney, NSW 2052, Australia.

Yann Gambin (Y)

Department of Molecular Medicine, School of Biomedical Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, University of New South Wales, Sydney, NSW 2052, Australia.

Sameer S Kulkarni (SS)

School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, NSW 2006, Australia.

Richard J Payne (RJ)

School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, NSW 2006, Australia.

Classifications MeSH